

REVOLUTIONIZING DETECTION OF DERMATOLOGICAL LESIONS



- ✓ 100% non-invasive
- ✓ Reliable results in 10 minutes
- ✓ Excellent Sensitivity and specificity values



AN UNRESOLVED CLINICAL NEED

- Skin cancer is the most common cancer worldwide in white populations.
- Melanoma, the most dangerous type, causes more than 9,000 deaths per year, especially due to its late diagnosis.
- Early detection saves lives; however, constant follow-ups has been indicated exclusively on people with high-risk factors.
- There is no convincing evidence on the follow-up of low-risk groups of patients.

quantusSKIN – ANALYSIS AND CLASSIFICATION OF DERMATOSCOPIC IMAGES FOR MALIGNANCY RISK ASSESSMENT

- Non-invasive: quantusSKIN is a non-invasive test that predicts the risk of malignancy of different skin lesions through a photograph or a dermoscopic image.
- Fast: quantusSKIN generates accurate results within a few minutes.

Sensitivity	Specificity	PPV	NPV
89,6%	85,2%	52,6%	97,8%

*Sensitivity: Proportion of negative cases correctly identified by the algorithm. It is the number of items correctly identified as negative out of the total number of negatives.

*Specificity: Proportion of positive cases correctly identified by the algorithm. It is the number of items correctly identified as positive over the actual total number of positives

*PPV: Positive Predicted Value.

*NPV: Negative Predicted Value.

How to use quantusSKIN?

Using quantusSKIN is simple, requiring only 3 steps:



1. Acquire a dermoscopic image




2. Upload the image into the app



3. Obtain the results

Step 1: Acquire a dermoscopic image

quantusSKIN requires a skin image in JPG or PNG format captured through a smartphone, reflex camera or similar, always free of active light filters. A dermatoscope can also be used when magnification markers or size markers are not used. There is a simple guide available within the app that shows how to perform these acquisitions.



Step 2: Use quantusSKIN medical app to analyze the image

The app is a simple tool that allows the user to send the image that wants to be analyzed by following three simple steps:



Upload

the JPG or PNG images



Select

the best image to be analyzed



Send

the sample for analysis

Step 3: Obtain the result within few minutes.

Screening test for malignant skin lesion 

Patient & Provider Information	
PATIENT NAME: Name & Surname	CLINIC NAME: Transrenal Biotech
PATIENT ID: 1234	BILLING/CODED CLINICIAN: Dr. Name Surname
quantusID: btech-115	REPORT DATE: dd/mm/yyyy 29/05/2020

Sample Information	Test Result quantusSKIN
	quantusSKIN ID: btech-115
ISSUE/REPORT DATE: dd/mm/yyyy 29/05/2020	quantusSKIN Risk: 
REPORT DATE: dd/mm/yyyy hh:mm 29/05/2020 13:34	Authorized sign-off:  Technical responsible: Alvaro Piver Moreno

DISCLAIMER:
quantusSKIN® offers an automatic assessment of the skin cancer risk using the quantitative texture analysis of a dermoscopic image of the skin lesion. Quality of image and a positive or relevant past record for skin following quantusSKIN requirements, quantusSKIN has been developed for skin cancer risk.

quantusSKIN is a medical device and is not to be used for any other purpose. quantusSKIN is a registered trademark of Transrenal Biotech S.L. (Transrenal Biotech S.L. is a company with registered office in Madrid (Spain) and is a company with registered office in Madrid (Spain) and is a company with registered office in Madrid (Spain)). quantusSKIN is a medical device and is not to be used for any other purpose. quantusSKIN is a registered trademark of Transrenal Biotech S.L. (Transrenal Biotech S.L. is a company with registered office in Madrid (Spain) and is a company with registered office in Madrid (Spain)).

WHEN TO USE quantusSKIN

quantusSKIN is a non-invasive, fast and easy-to-use test that allows the detection of malignant dermatological lesions through dermoscopic images.

Its technology is based on quantitative analysis of dermoscopic image texture. By simply analyzing and classifying images, quantusSKIN determines within minutes the probability of a skin lesion.

quantusSKIN design has been focused on general population with the purpose of being a tool for the detection of malignant skin lesions such as melanoma, basal cell carcinoma or squamous cell carcinoma. Moreover, it allows the screening of patients with risk factors and the prioritization in waiting lists.

quantusSKIN classifies skin lesions in benign or malignant without the need of or in addition to visual inspection from a specialist via a dermatoscope. The specialist, classifies the images by visual patterns and quantusSKIN gives a percentage risk of malignancy.



AN INNOVATIVE MEDICAL SOLUTION

- ✓ **Unrestricted 24-hours access:** Through an internet connection it is possible to use quantusSKIN and review the results at any time and from anywhere.
- ✓ **No installation required:** It does not require the download or installation of any software.
- ✓ **High compatibility:** quantusSKIN is compatible with most browsers. It can be used for web-based as well as primary devices of ophthalmology, optometry and primary care.

quantusSKIN OFFERS HIGH ECONOMIC VALUE

- ✓ **NO initial investment in infrastructure required!**
- ✓ **Pay-as-you-go: Pay only for each test you order!**
- ✓ **Add more value to your clinic and increase your profits!**

WHY DOES quantusSKIN WORK?

Over the past few years, research has been focused on automated algorithms to improve current imaging-based clinical diagnosis. The rise of Artificial Intelligence techniques, and especially Deep Learning, has increased the number of studies using this type of algorithm for dermatologic diagnostics.

quantusSKIN is a cutting-edge Artificial Intelligence method, based on the newest generation of Deep Learning.

Different studies carried out have proven the existing correlation between the quantitative analysis method proposed by quantusSKIN. The technology is based on performing a quantitative analysis of the texture of the cutaneous Nevus image obtained using a smartphone, reflex camera or dermatoscope. This analysis allows to identify patterns associated with specific pathologies and produce high-quality assessment of a malignancy skin lesion. According to the literature, currently tests and tools used by the dermatologist give an individual sensitivity of 75-84%. While quantusSKIN has obtained in its tests a sensitivity of 85.6%.






Accurate



Effective



Fast

**Give it a try..
Contact us!**





Email.: sales@transmuralbiotech.com

 **quantustb**  **TRANSMURAL BIOTECH**



**TRANSMURAL
BIOTECH**

 **+34 931 190 929**

 **+34 626 667 989**

**Transmural Biotech S.L., CIF: B65084675.
C/ Beethoven 15 Planta 4 Desp. 18 08021 Barcelona**